Advances on disease modifying drugs for post-stroke epilepsy

doi:10.3969/j.issn.1672-6731.2023.03.004

Abstract

Abstract: Post-stroke epilepsy (PSE) patients generally respond well to low-dose antiepileptic seizure medicine (ASM), but some patients still develop drug-resistant epilepsy (DRE). Thus, the development of effective drugs that can prevent or reverse epilepsy and disease modifying therapy (DMT) drugs are urgently needed. It was proved that new ASM such as levetiracetam (LVT), lamotrigine (LTG) and zonisamide, natural compounds such as cannabidiol and polyphenolic compounds, mitochondrial antioxidants and non-steroidal anti-inflammatory drug (NSAID) can not only control seizure but also intervene the occurrence of PSE, playing anti-epileptogenic and DMT role. This article intends to further summarize DMT drugs for PSE, providing new research ideas for PSE modifying therapy.

Key words: Epilepsy, Stroke, Anticonvulsants, Disease modifying therapy (not in MeSH), Neuroprotection, Review

摘要： 脑卒中后癫痫患者对低剂量抗癫痫发作药物治疗反应良好，但仍有部分患者进展为耐药性癫痫，因此亟待研发有效预防或逆转癫痫发生和发展且具备疾病修饰治疗作用的药物。业已证实，左乙拉西坦、拉莫三嗪、唑尼沙胺等新型抗癫痫发作药物，大麻二酚、多酚类化合物等天然化合物，线粒体抗氧化药、非甾体抗炎药等药物不仅能控制癫痫发作，甚至能够阻止脑卒中后癫痫的发生，以此发挥抗癫痫发生及疾病修饰治疗作用。本文对具有疾病修饰治疗作用的药物进行归纳，以为脑卒中后癫痫的疾病修饰治疗提供新的研究思路。

关键词: 癫痫, 卒中, 抗惊厥药, 疾病修饰治疗（非MeSH词）, 神经保护, 综述

XU Ying, QI Jing, WANG Qun. Advances on disease modifying drugs for post-stroke epilepsy[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2023, 23(3): 167-172.

徐莹, 齐婧, 王群. 脑卒中后癫痫药物修饰治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(3): 167-172.

/ / Recommend / Download Citations

URL: http://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2023.03.004

http://journal11.magtechjournal.com/cjcnn/EN/Y2023/V23/I3/167

References

[1] Krueger H, Koot J, Hall RE, O'Callaghan C, Bayley M, Corbett D. Prevalence of individuals experiencing the effects of stroke in Canada:trends and projections[J]. Stroke, 2015, 46:2226-2231.
[2] Siebenbrodt K, Strzelczyk A, Rosenow F. Epilepsy in old age[J]. Nervenarzt, 2020, 91:353-361.
[3] Łukasiuk K, Lasoń W. Emerging molecular targets for anti-epileptogenic and epilepsy modifying drugs[J]. Int J Mol Sci, 2023, 24:2928.
[4] Feyissa AM, Hasan TF, Meschia JF. Stroke-related epilepsy[J]. Eur J Neurol, 2019, 26:18-e3.
[5] Galovic M, Ferreira-Atuesta C, Abraira L, Döhler N, Sinka L, Brigo F, Bentes C, Zelano J, Koepp MJ. Seizures and epilepsy after stroke:epidemiology, biomarkers and management[J]. Drugs Aging, 2021, 38:285-299.
[6] Nicolo JP, O'Brien TJ, Kwan P. Role of cerebral glutamate in post-stroke epileptogenesis[J]. Neuroimage Clin, 2019, 24:102069.
[7] Yoshimura H, Tanaka T, Fukuma K, Matsubara S, Motoyama R, Mizobuchi M, Matsuki T, Manabe Y, Suzuki J, Kobayashi K, Shimotake A, Nishimura K, Onozuka D, Kawamoto M, Koga M, Toyoda K, Murayama S, Matsumoto R, Takahashi R, Ikeda A, Ihara M; PROPOSE Study Investigators. Impact of seizure recurrence on 1-year functional outcome and mortality in patients with poststroke epilepsy[J]. Neurology, 2022, 99:e376-384.
[8] Falco-Walter J. Epilepsy definition, classification, pathophysiology, and epidemiology[J]. Semin Neurol, 2020, 40:617-623.
[9] Candelario-Jalil E, Dijkhuizen RM, Magnus T. Neuroinflammation, stroke, blood-brain barrier dysfunction, and imaging modalities[J]. Stroke, 2022, 53:1473-1486.
[10] Verhoog QP, Holtman L, Aronica E, van Vliet EA. Astrocytes as guardians of neuronal excitability:mechanisms underlying epileptogenesis[J]. Front Neurol, 2020, 11:591690.
[11] Shi XS, Song SM, Xu JY. The past, present and future of drug therapy for epilepsy[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2023, 23:78-88[.史向松, 宋苏蒙, 徐建洋. 癫痫药物治疗的过去、现在与未来[J]. 中国现代神经疾病杂志, 2023, 23:78-88.]
[12] Müller T, Mueller BK, Riederer P. Perspective:treatment for disease modification in chronic neurodegeneration[J]. Cells, 2021, 10:873.
[13] Steriade C, French J, Devinsky O. Epilepsy:key experimental therapeutics in early clinical development[J]. Expert Opin Investig Drugs, 2020, 29:373-383.
[14] Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia[J]. Ann Neurol, 2003, 53:693-702.
[15] He J, Zhang X, He W, Xie Y, Chen Y, Yang Y, Chen R. Neuroprotective effects of zonisamide on cerebral ischemia injury via inhibition of neuronal apoptosis[J]. Braz J Med Biol Res, 2021, 54:e10498.
[16] Polat İ, Cilaker Mıcılı S, Çalışır M, Bayram E, Yiş U, Ayanoğlu M, Okur D, Edem P, Paketçi C, Tuğyan K, Yılmaz O, Hız Kurul S. Neuroprotective effects of lacosamide and memantine on hyperoxic brain injury in rats[J]. Neurochem Res, 2020, 45:1920-1929.
[17] Schidlitzki A, Bascuñana P, Srivastava PK, Welzel L, Twele F, Töllner K, Käufer C, Gericke B, Feleke R, Meier M, Polyak A, Ross TL, Gerhauser I, Bankstahl JP, Johnson MR, Bankstahl M, Löscher W. Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy[J]. Neurobiol Dis, 2020, 134:104664.
[18] Litvinova SA, Kutepova IS, Voronina TA, Petrunina AA. Levetiracetam effect on behavioral and electrophysiological parameters in rat model of global brain ischemia[J]. Epilepsy Res, 2020, 167:106466.
[19] Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model[J]. Proc Natl Acad Sci USA, 2012, 109:E2895-2903.
[20] Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia[J]. Seizure, 2001, 10:287-293.
[21] Peter-Derex L, Philippeau F, Garnier P, André-Obadia N, Boulogne S, Catenoix H, Convers P, Mazzola L, Gouttard M, Esteban M, Fontaine J, Mechtouff L, Ong E, Cho TH, Nighoghossian N, Perreton N, Termoz A, Haesebaert J, Schott AM, Rabilloud M, Pivot C, Dhelens C, Filip A, Berthezène Y, Rheims S, Boutitie F, Derex L. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2022, 21:781-791.
[22] Ge YX, Lin YY, Bi QQ, Chen YJ. Brivaracetam prevents the over-expression of synaptic vesicle protein 2A and rescues the deficits of hippocampal long-term potentiation in vivo in chronic temporal lobe epilepsy rats[J]. Curr Neurovasc Res, 2020, 17:354-360.
[23] Wang J, Chen Y, Wang Q, van Luijtelaar G, Sun M. The effects of lamotrigine and ethosuximide on seizure frequency, neuronal loss, and astrogliosis in a model of temporal-lobe epilepsy[J]. Brain Res, 2019, 1712:1-6.
[24] Sendrowski K, Sobaniec W. Hippocampus, hippocampal sclerosis and epilepsy[J]. Pharmacol Rep, 2013, 65:555-565.
[25] Caccamo D, Pisani LR, Mazzocchetti P, Ientile R, Calabresi P, Pisani F, Costa C. Neuroprotection as a potential therapeutic perspective in neurodegenerative diseases:focus on antiepileptic drugs[J]. Neurochem Res, 2016, 41:340-352.
[26] Kumar B, Medhi B, Modi M, Saikia B, Attri SV, Patial A. A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures[J]. Inflammopharmacology, 2018, 26:1125-1131.
[27] Lazzarotto L, Pflüger P, Regner GG, Santos FM, Aguirre DG, Brito VB, Moura DJ, Dos Santos NM, Picada JN, Parmeggiani B, Frusciante MR, Leipnitz G, Pereira P. Lacosamide improves biochemical, genotoxic, and mitochondrial parameters after PTZ-kindling model in mice[J]. Fundam Clin Pharmacol, 2021, 35:351-363.
[28] Gáll Z, Kelemen K, Mihály I, Salamon P, Miklóssy I, Zsigmond B, Kolcsár M. Role of lacosamide in preventing pentylenetetrazole kindling-induced alterations in the expression of the gamma-2 subunit of the GABAA receptor in rats[J]. Curr Mol Pharmacol, 2020, 13:251-260.
[29] Choi HY, Park JH, Chen BH, Shin BN, Lee YL, Kim IH, Cho JH, Lee TK, Lee JC, Won MH, Ahn JH, Tae HJ, Yan BC, Hwang IK, Cho JH, Kim YM, Kim SK. Increases of catalase and glutathione peroxidase expressions by lacosamide pretreatment contributes to neuroprotection against experimentally induced transient cerebral ischemia[J]. Neurochem Res, 2016, 41:2380-2390.
[30] Gul A, Mehreen S. Effectiveness of Lacosamide on everyday cognitive deficits, psychiatric symptoms and resilience in patients with epilepsy[J]. J Pak Med Assoc, 2020, 70:1611-1615.
[31] Winter Y, Uphaus T, Sandner K, Klimpe S, Stuckrad-Barre SV, Groppa S. Efficacy and safety of antiseizure medication in post-stroke epilepsy[J]. Seizure, 2022, 100:109-114.
[32] Nicolo JP, Chen Z, Moffat B, Wright DK, Sinclair B, Glarin R, Neal A, Thijs V, Seneviratne U, Yan B, Cloud G, O'Brien TJ, Kwan P. Study protocol for a phaseⅡ randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke[J]. BMJ Open, 2021, 11:e043488.
[33] Guennoun R. Progesterone in the brain:hormone, neurosteroid and neuroprotectant[J]. Int J Mol Sci, 2020, 21:5271.
[34] Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy[J]. Exp Neurol, 2006, 201:519-524.
[35] Golub V, Reddy DS. Cannabidiol therapy for refractory epilepsy and seizure disorders[J]. Adv Exp Med Biol, 2021, 1264:93-110.
[36] Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, Wang Y, Liang C. Overview of cannabidiol (CBD) and its analogues:structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease[J]. Eur J Med Chem, 2020, 192:112163.
[37] Gaston TE, Martin RC, Szaflarski JP. Cannabidiol (CBD) and cognition in epilepsy[J]. Epilepsy Behav, 2021, 124:108316.
[38] Zhang K, Liu Q, Luo L, Feng X, Hu Q, Fan X, Mao S. Neuroprotective effect of alpha-asarone on the rats model of cerebral ischemia-reperfusion stroke via ameliorating glial activation and autophagy[J]. Neuroscience, 2021, 473:130-141.
[39] Shekh-Ahmad T, Lieb A, Kovac S, Gola L, Christian Wigley W, Abramov AY, Walker MC. Combination antioxidant therapy prevents epileptogenesis and modifies chronic epilepsy[J]. Redox Biol, 2019, 26:101278.
[40] Xing J, Han D, Xu D, Li X, Sun L. CREB protects against temporal lobe epilepsy associated with cognitive impairment by controlling oxidative neuronal damage[J]. Neurodegener Dis, 2019, 19:225-237.
[41] Santini E, Turner KL, Ramaraj AB, Murphy MP, Klann E, Kaphzan H. Mitochondrial superoxide contributes to hippocampal synaptic dysfunction and memory deficits in angelman syndrome model mice[J]. J Neurosci, 2015, 35:16213-16220.
[42] Huang R, Zhu Y, Lin L, Song S, Cheng L, Zhu R. Solid lipid nanoparticles enhanced the neuroprotective role of curcumin against epilepsy through activation of Bcl-2 family and P38 MAPK pathways[J]. ACS Chem Neurosci, 2020, 11:1985-1995.
[43] Dhir A. Natural polyphenols in preclinical models of epilepsy[J]. Phytother Res, 2020, 34:1268-1281.
[44] Taskiran AS, Tastemur Y. The role of nitric oxide in anticonvulsant effects of lycopene supplementation on pentylenetetrazole-induced epileptic seizures in rats[J]. Exp Brain Res, 2021, 239:591-599.
[45] Radu BM, Epureanu FB, Radu M, Fabene PF, Bertini G. Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy[J]. Epilepsy Res, 2017, 131:15-27.
[46] Zhao T, Ding Y, Feng X, Zhou C, Lin W. Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam[J]. Medicine (Baltimore), 2020, 99:e23577.
[47] Wang Q, Wei HC, Zhou SJ, Li Y, Zheng TT, Zhou CZ, Wan XH. Hyperoside:a review on its sources, biological activities, and molecular mechanisms[J]. Phytother Res, 2022, 36:2779-2802.
[48] Cao J, Tang C, Gao M, Rui Y, Zhang J, Wang L, Wang Y, Xu B, Yan BC. Hyperoside alleviates epilepsy-induced neuronal damage by enhancing antioxidant levels and reducing autophagy[J]. J Ethnopharmacol, 2020, 257:112884.

Please choose a citation manager

Content to export